Loxo Oncology Inc.

8 trials 1 recruiting Commercial sponsor

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

1 Recruiting

7 Completed trials

17 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase I (FiH)

Phase III: 5 Phase I/II: 1 Phase I (FiH): 2

Oversight events:

1 serious breach 1 corrective measure across 2 trials

View oversight register →

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Medullary thyroid cancer 2 B-cell small lymphocytic lymphoma 1 Non-small cell lung cancer 1 Non-Hodgkin's lymphoma 1 Central nervous system neoplasm 1

Top IMPs

PIRTOBRUTINIB 3 SELPERCATINIB 1

All trials

8 total

A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting

2023-507699-38-00 Phase III 9 countries
A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended

2024-511599-33-00 Phase III 10 countries
A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended

2023-507698-16-00 Phase III 11 countries
A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended

2023-507697-40-00 Phase III 11 countries PIRTOBRUTINIB
A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended

2023-507695-52-00 Phase III 11 countries PIRTOBRUTINIB
A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tu… Ended

2023-507703-63-00 Phase I/II 5 countries SELPERCATINIB
A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumors. Ended

2023-507702-13-00 Phase I (FiH) 5 countries
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL… Ended

2023-509270-37-00 Phase I (FiH) 3 countries PIRTOBRUTINIB

Showing 1–8 of 8 trials

← All sponsors A–Z